3,5,4′-Tri-O-Acetylresveratrol Attenuates Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome via MAPK/SIRT1 Pathway

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Ma, Lijie ^a   Zhao, Yilin ^a   Wang, Ruixuan ^a   Chen, Tingting ^b   Li, Wangping ^a   Nan, Yandong ^a   Liu, Xueying ^c   Jin, Faguang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XIJING UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,5,4' TRI O ACETYLRESVERATROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTECTIVE AGENT; RESPIRATORY TRACT AGENT; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 3,5,4'-TRI-O-ACETYLRESVERATROL; ACETIC ACID DERIVATIVE; AUTACOID; RESVERATROL; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE COMPARISON; IN VITRO STUDY; IN VIVO STUDY; LIPOPOLYSACCHARIDE-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME; LUNG ALVEOLUS; LUNG ALVEOLUS WALL; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RESPIRATORY DISTRESS; SIGNAL TRANSDUCTION; WATER CONTENT; ANIMAL; CAPILLARY PERMEABILITY; CELL CULTURE; DRUG EFFECTS; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACETATES; ANIMALS; CAPILLARY PERMEABILITY; CELLS, CULTURED; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; MICE; RESPIRATORY DISTRESS SYNDROME, ADULT; SIRTUIN 1; STILBENES;

EID: 84948823034     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/143074     Document Type: Article

References (37)

1. Y. Koh, "Update in acute respiratory distress syndrome, " Journal of Intensive Care, vol. 2, article 2, 2014.
2. J. Villar, J. Blanco, J. M. Anon et al. , "The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation, " Intensive Care Medicine, vol. 37, no. 12, pp. 1932-1941, 2011.
3. F. MafradeLima, K. T. Naves, A. H. Machado, R. Albertini, A. B. Villaverde, and F. Aimbire, "Lung inflammation and endothelial cell damage are decreased after treatment with phototherapy (PhT) in amodel of acute lung injury induced by Escherichia coli lipopolysaccharide in the rat, " Cell Biology International, vol. 33, no. 12, pp. 1212-1221, 2009.
4. W. Jing, M. Chunhua, and W. Shumin, "Effects of acteoside on lipopolysaccharide-induced inflammation in acute lung injury via regulation of NF-kappaB pathway in vivo and in vitro, " Toxicology and Applied Pharmacology, vol. 285, no. 2, pp. 128-135, 2015.
5. D. G. Geboers, F. M. de Beer, A. M. Boer et al. , "Plasma suPAR as a prognostic biological marker for ICU mortality in ARDS patients, " Intensive Care Medicine, vol. 41, no. 7, pp. 1281-1290, 2015.
6. S. Khan, R. J. Choi, O. Shehzad et al. , "Molecular mechanism of capillarisin-mediated inhibition of MyD88/TIRAP inflammatory signaling in in vitro and in vivo experimental models, " Journal of Ethnopharmacology, vol. 145, no. 2, pp. 626-637, 2013.
7. N. Bhaskaran, S. Shukla, J. K. Srivastava, and S. Gupta, "Chamomile: an anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity, " International Journal of Molecular Medicine, vol. 26, no. 6, pp. 935-940, 2010.
8. M. S. Hayden and S. Ghosh, "NF-kappaB in immunobiology, " Cell Research, vol. 21, no. 2, pp. 223-244, 2011.
9. Y.-C. Chi, S.-P. Lin, and Y.-C. Hou, "A new herb-drug interaction of Polygonum cuspidatum, a resveratrol-rich nutraceutical, with carbamazepine in rats, " Toxicology and Applied Pharmacology, vol. 263, no. 3, pp. 315-322, 2012.
10. R. K. Vella, C. Pullen, F. R. Coulson, and A. S. Fenning, "Resveratrol prevents cardiovascular complications in the SHR/STZ rat by reductions in oxidative stress and inflammation, " BioMed Research International, vol. 2015, Article ID 918123, 8 pages, 2015.
11. Q. Xu and L.-Y. Si, "Resveratrol role in cardiovascular and metabolic health and potentialmechanisms of action, " Nutrition Research, vol. 32, no. 9, pp. 648-658, 2012.
12. P. Liu, H. Liang, Q. Xia et al. , "Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression, " Clinical and Translational Oncology, vol. 15, no. 9, pp. 741-746, 2013.
13. Y.-Q. Xue, J.-M. Di, Y. Luo, K.-J. Cheng, X. Wei, and Z. Shi, "Resveratrol oligomers for the prevention and treatment of cancers, " Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 765832, 9 pages, 2014.
14. M. M. Poulsen, K. Fjeldborg, M. J. Ornstrup, T. N. Kjær, M. K. Nøhr, and S. B. Pedersen, "Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes, " Biochimica et Biophysica Acta, vol. 1852, no. 6, pp. 1124-1136, 2015.
15. Z. Liu, C. Jiang, J. Zhang, B. Liu, andQ. Du, "Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation ofAMP-Activated protein kinase and sirtuin 1 activities, " Journal of Diabetes, 2015.
16. T. Finkel, C.-X. Deng, and R. Mostoslavsky, "Recent progress in the biology and physiology of sirtuins, " Nature, vol. 460, no. 7255, pp. 587-591, 2009.
17. T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis Jr. , andU. K. Walle, "High absorption but very low bioavailability of oral resveratrol in humans, "DrugMetabolismandDisposition, vol. 32, no. 12, pp. 1377-1382, 2004.
18. Y. Dobrydneva, R. L. Williams, G. Z. Morris, and P. F. Blackmore, "Dietary phytoestrogens and their synthetic structural analogues as calcium channel blockers in human platelets, " Journal of Cardiovascular Pharmacology, vol. 40, no. 3, pp. 399-410, 2002.
19. L. Liang, X. Liu, Q. Wang, S. Cheng, S. Zhang, and M. Zhang, "Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3, 5, 4-tri-O-Acetylresveratrol in rats, " Phytomedicine, vol. 20, no. 6, pp. 558-563, 2013.
20. L. Ma, Y. Li, Y. Zhao et al. , "3, 5, 4-Tri-O-Acetylresveratrol ameliorates seawater exposure-induced lung injury by upregulating connexin 43 expression in lung, "Mediators of Inflammation, vol. 2013, Article ID 182132, 8 pages, 2013.
21. K. Koide, S. Osman, A. L. Garner et al. , "The use of 3, 5, 4-tri-Oacetylresveratrol as a potential prodrug for resveratrol protects mice from -irradiation-induced death, " ACS Medicinal Chemistry Letters, vol. 2, no. 4, pp. 270-274, 2011.
22. B. Zhang, Z.-Y. Liu, Y.-Y. Li et al. , "Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice, " European Journal of Pharmaceutical Sciences, vol. 44, no. 5, pp. 573-579, 2011.
23. D. R. Janz and L. B. Ware, "Biomarkers of ALI/ARDS: pathogenesis, discovery, and relevance to clinical trials, " Seminars in Respiratory and Critical Care Medicine, vol. 34, no. 4, pp. 537-548, 2013.
24. L. B. Ware, "Autopsy in ARDS: insights into natural history, "The Lancet Respiratory Medicine, vol. 1, no. 5, pp. 352-354, 2013.
25. L. W. Soromou, N. Chen, L. Jiang et al. , "Astragalin attenuates lipopolysaccharide-induced inflammatory responses by downregulating NF-kappaB signaling pathway, " Biochemical and Biophysical Research Communications, vol. 419, no. 2, pp. 256-261, 2012.
26. S. Herold, N. M. Gabrielli, and I. Vadasz, "Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction, " American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 305, no. 10, pp. L665-L681, 2013.
27. T. Zhu, D.-X. Wang, W. Zhang et al. , "Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-B, " PLoS ONE, vol. 8, no. 2, Article ID e56407, 2013.
28. D. El Kebir, L. Jozsef, W. Pan, and J. G. Filep, "Myeloperoxidase delays neutrophil apoptosis through CD11b/CD18 integrins and prolongs inflammation, " Circulation Research, vol. 103, no. 4, pp. 352-359, 2008.
29. S. K. Cribbs and G. S. Martin, "Stem cells in sepsis and acute lung injury, " The American Journal of the Medical Sciences, vol. 341, no. 4, pp. 325-332, 2011.
30. I. Muller, S. Beissert, and D. Kulms, "Anti-Apoptotic NF-B and 'gain of function' mutp53 in concert act pro-Apoptotic in response to UVB+IL-1 via enhanced TNF production, " Journal of Investigative Dermatology, vol. 135, no. 3, pp. 851-860, 2015.
31. R. Bianchi, I. Giambanco, and R. Donato, "S100B/RAGEdependent activation of microglia via NF-kappaB and AP-1 Coregulation of COX-2 expression by S100B, IL-1beta and TNFalpha, " Neurobiology of Aging, vol. 31, no. 4, pp. 665-677, 2010.
32. C. X. Jian, M. Z. Li, W. Y. Zheng et al. , "Tormentic acid inhibits LPS-induced inflammatory response in human gingival fibroblasts via inhibition of TLR4-mediated NF-B andMAPK signalling pathway, " Archives of Oral Biology, vol. 60, no. 9, pp. 1327-1332, 2015.
33. J. Yamana, L. Santos, and E. Morand, "Enhanced induction of LPS-induced fibroblast MCP-1 by interferon-: involvement of JNK and MAPK phosphatase-1, " Cellular Immunology, vol. 255, no. 1-2, pp. 26-32, 2009.
34. N. W. Lucchi and J. M. Moore, "LPS induces secretion of chemokines by human syncytiotrophoblast cells in a MAPKdependent manner, " Journal of Reproductive Immunology, vol. 73, no. 1, pp. 20-27, 2007.
35. S. Cetrullo, S. D'Adamo, B. Tantini, R. M. Borzi, and F. Flamigni, "mTOR, AMPK, and Sirt1: key players in metabolic stress management, " Critical Reviews in Eukaryotic Gene Expression, vol. 25, no. 1, pp. 59-75, 2015.
36. C. Ehlting, O. Böhmer, M. J. Hahnel et al. , "Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38MAPK/MK2, " Cellular Signalling, vol. 27, no. 3, pp. 555-567, 2015.
37. A. D. Napper, J. Hixon, T. McDonagh et al. , "Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1, " Journal ofMedicinal Chemistry, vol. 48, no. 25, pp. 8045-8054, 2005.